Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Colorectal Neoplasms × idelalisib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 9 Waldenstrom Macroglobulinemia 5 Lymphoma, Follicular 5 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Hodgkin Disease 1 Colorectal Neoplasms 1

Interventions

Bevacizumab 203 Fluorouracil 195 Irinotecan 190 Oxaliplatin 185 Leucovorin 176 Capecitabine 131 Cetuximab 127 Panitumumab 61 Folfox protocol 43 regorafenib 39 Radiotherapy 36 IFL protocol 35 pembrolizumab 34 HMPL-013 30 trifluridine tipiracil drug combination 28 Nivolumab 26 Neoadjuvant Therapy 23 Drug Therapy 20 tislelizumab 16 Celecoxib 16 XELOX 15 aflibercept 14 Trifluridine 14 Chemotherapy, Adjuvant 14 sintilimab 13 atezolizumab 13 Trastuzumab 13 Gemcitabine 13 durvalumab 12 apatinib 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05725200 2023-02-21

EVIDENT

Oslo University Hospital

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡